Share on Facebook Share on Twitter Share on Google+

News from the ICAAC conference 2012

The 52 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) took place in San Francisco this week.

The Conference, hosted by the American Society for Microbiology, aims to meet the needs of health professionals who specialise in infectious diseases.This page summarises some of the HIV-related presentations and links to further info.

Promising new fusion inhibitor

A new fusion inhibitor, albuvirtide, has been found to be safe, well tolerated and may be suitable for once-weekly dosing, according to two recent clinical trials in China.

Fusion inhibitors are thought to be useful for people who have multi-drug resistant HIV, however only one - enfuvirtide (formerly known as T-20), is approved for use.

Enfuvirtide is currently not a very practical treatment option as it must be administered by subcutaneous injection twice a day.

Albuvirtide, however, has a long half life, which suggests it may be effective with less frequent dosing. The first (and larger) of the Chinese trials found that antiviral activity was still occurring six - ten days after a single dose via intravenous infusion. More studies are planned.

More info

Long-acting fusion inhibitor albuvirtide looks promising in early studies - AIDSMAP

Stribild: potent, fewer side effects - but will people use it?

Recently FDA approved four-in-one pill Stribild (previously known as the 'Quad' pill) is at least as effective as comparative treatment regimens and is associated with fewer adverse events, according to an analysis of phase II and III trials.

Stribild contains integrase inhibitor elvitegravir, boosting agent cobicistat, and tenofovir DF/emtricitabine.

David Ward from Dupont Circle Physicians Group presented an integrated analysis of safety and efficacy in three trials that had a total of 748 people taking Stribild.

In the comparison arms a total of 375 people were taking Atripla and 355 were on ritonavir-boosted atazanavir.

Stribild was found to be generally safe and well-tolerated. Rates of serious adverse events were comparable to those on the comparison arms. People taking Stribild reported fewer neuropsychiatric side-effects, rashes, and less bilirubin elevation.

In spite of these promising results, and the excitement generated by Stribild's approval, preliminary findings from another study suggest that single-pill regimens may not improve adherence (consistent taking of medication as prescribed).

Lead researcher Cal Cohen reported about 10% non-adherence in a retrospective analysis of a US database of pharmacy and medical claims between January 2009 and the end of 2011. People on single-pill regimens were no more likely to take their meds than those on other regimens.

The analysis also found that people prescribed single table regimens, even if not taking their treatments consistently, were not hospitalised as often as people who were not fully adherent. On this basis Cohen recommended simpler regimens would be beneficial for people who are partially adherent to treatment.

More info

Integrated analysis shows 'Quad' pill has potent activity with fewer side-effects - AIDSMAP

Combo Pills Fail to Get More HIV Patients on Meds - MedPageToday

More News

This page was published on 13 September, 2012